Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 33Not yet recruiting 18Unknown 16Completed 10Withdrawn 6Terminated 5Active not recruiting 5Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Biliary Tract Carcinoma 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 7Biopsy 6Nivolumab 4Capecitabine 4Bevacizumab 4Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Cyclophosphamide 3Cisplatin 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2decitabine and cedazuridine drug combination 2daratumumab 2Vincristine 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Etoposide 2Epirubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Immunotherapy × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡